AgingResearch.NewsJoin free

Transposon Therapeutics

CompanyUnited States

Wikidata

Transposon Therapeutics develops one asset, in phase 2 (TPN-101 in Alzheimer's disease). Mostly small molecule; based in the United States.

1
Asset
Furthest stage
Phase 2
Raised
$54.4M
0
Trials
1
Signal

Pipeline

1

  • TPN-101

    Inhibits LINE-1 reverse transcriptase.

    Phase 2, Small molecule, Alzheimer's disease, C9orf72-Related amyotrophic lateral sclerosis

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Funding rounds and grants3
  • People24
  • Signals1
  • Similar companies6

Papers

Intelligence